intismeran — Topline data
2026
Moderna expects Phase 3 adjuvant melanoma data potentially in 2026.Source filing
MRNA biotech catalysts & pipeline
MODERNA INC · Data as of 2026-09-08
Upcoming catalysts
mNEXSPIKE (mRNA-1283) — NDA/BLA submission
2026
The Company has filed and is targeting 2026 approvals in Australia, the EU, Japan and Taiwan.Source filing
mresvia — Topline data
2026
Moderna's RSV vaccine, mRESVIA®, is in an ongoing Phase 3 heterologous revaccination study with data expected in 2026.Source filing
mRNA-1010 — NDA/BLA submission
2026
The Company's mRNA-1010 regulatory filings are under review in Europe, Canada and Australia and potential approvals are expected to begin in 2026.Source filing
mRNA-3927 — Topline data
2026
Moderna expects potential data in 2026.Source filing
mRNA-4359 — Topline data
2026
The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC, and the Company expects a potential Phase 2 data readout in 2026.Source filing
mRNA-1010 — Regulatory decision
Sep 2026–Apr 2027
Moderna expects the earliest potential approvals for mRNA-1010 to begin in late 2026 or early 2027, subject to those ongoing regulatory reviews.Source filing